Author:
Moch H.,Sauter G.,Gasser T. C.,Buchholz N.,Bubendorf L.,Richter J.,Jiang F.,Dellas A.,Mihatsch M. J.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Devesa S, Silverman D, McLaughlin J (1990) Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control 1:133
2. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531
3. Hall P, Lane D (1994) p53 in tumor pathology: Can we trust immunocytochemistry? J Pathology 172:1
4. Uhlman D, Nguyen P, Manivel J, et al. (1994) Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 86:21470
5. Oda H, Nakarsuru Y, Ishikawa T (1995) Mutations of the p53 gene and p53 overexpression are associated with sarcomatoid transformation in renal cell carcinoma. Cancer Res 55:658
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma;Journal of Experimental & Clinical Cancer Research;2021-08-12
2. Circular RNA_0074027 participates in cell proliferation, apoptosis and metastasis of colorectal cancer cells through regulation of miR‑525‑3p;Molecular Medicine Reports;2021-03-05
3. Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma;Urologic Clinics of North America;2016-02
4. Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients;South Asian Journal of Cancer;2016-01
5. Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism;Cancer Letters;2014-10